메디채널

주메뉴 바로가기
본문 바로가기

기상청 제공

닫기

라이프

FDA Grants Fast Track Designation for AJ201, a First-in-Class Therapy for Kenndy's Disease

TAIPEI, Oct. 23, 2025 -- AnnJi Pharmaceutical Co., Ltd. (AnnJi, TWSE: 7754) today announced that the U.S. Food & Drug Administration (FDA) has granted Fast Track Designation for AJ201, the first-in-class for therapy for spinal and bulbar muscular atrophy (SBMA, also known as Kennedy's disease). "Receiving the Fast Track Designation for AJ201 marks a significant milestone for AnnJi," said Dr. Wendy Huang, CEO and Chairperson of the Board of AnnJi. "Alongside the Orphan Drug Designations granted by both the U.S. FDA and EMA, this recognition reinforces AJ201's potentia
- 김갑성 기자
- 2025-10-23 11:24
Hill's Pet Nutrition Announces 2025 Hill's Global Symposium - "Strong Science, Long Lives" - to Advance Senior Pet Care

Registration now open for veterinary professionals in Asia and Australia to access the latest insights in geroscience and nutritional strategies for aging companions OVERLAND PARK, Kan., Oct. 23, 2025 -- Hill's Pet Nutrition (Hill's), a global leader in science-led nutrition, today announced the 2025 Hill's Global Symposium, focusing on specialized care for aging pets. The Symposium is one of the largest free global education opportunities available for veterinary professionals worldwide. Registration is now open for the event, titled "Strong Science, Long Lives,&q
- 김갑성 기자
- 2025-10-23 08:00
힐스 펫 뉴트리션은 "Strong Science, Long Lives"라는 주제로 고령 반려동물 케어 증진을 위한 2025 힐스 글로벌 심포지엄 개최를 발표했습니다

아시아와 호주의 수의 전문가들이 노화 과학 및 영양 전략에 대한 최신 인사이트를 얻을 수 있는 심포지엄 등록이 시작되었습니다 캔자스주 오버랜드 파크, 2025년 10월 23일 -- 과학 기반 영양을 추구하는 글로벌 선두기업 힐스 펫 뉴트리션은 오늘 고령 반려동물을 위한 특별한 케어에 초점을 맞춘 '2025 힐스 글로벌 심포지엄' 개최를 발표했습니다. 이번 심포지엄은 전 세계 수의 전문가들에게 무료로 제공되는 가장 큰 규모의 글로벌 교육 기회 중 하나입니다. 노령 반려동물 건강을 위한 힐스의 오랜 연구를 바탕으로 "Strong Science, Long Lives"라는 주제로 개최되는 이번 행사의 등록이 시작되었습니다. 참가 희망자는 '힐스 벳 아카데미(Hill's Veterinary Academy)' 플랫폼을 통해 라이브 스트리밍에 등록할 수 있으며, 온라인 등록 시, 실시간 행사 종료 후에도 모든 세션을 VOD로 다시 시청할 수 있습니다. 지역별 라이브 스트리밍 일정은 다음과 같습니다: 호주/뉴질랜드: 10월 29-30일 한국, 태국, 대만, 일본: 11
- 김갑성 기자
- 2025-10-23 07:00
Telix Doses First Patient in SOLACE Trial for Metastatic Bone Pain

MELBOURNE, Australia and INDIANAPOLIS, Oct. 23, 2025 -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today announces that it has dosed the first patient in a Phase 1 clinical trial of TLX090 (153Samarium (Sm)-DOTMP), a therapeutic radiopharmaceutical candidate for treating pain associated with bone metastasis. TLX090 is designed to deliver targeted radiation to bone tumors while minimizing damage to surrounding healthy tissues. SOLACE (Samarium Optimized for Long-lasting Analgesia in Cancerous End-stage bone pain) is an open-label Phase
- 김갑성 기자
- 2025-10-23 04:00
Charming Medical Limited Announces Closing of Initial Public Offering

HONG KONG, Oct. 23, 2025 -- Charming Medical Limited (Nasdaq: MCTA) (the "Company"), a Hong Kong-based provider of Traditional Chinese Medicine (TCM)-inspired therapies and products, today announced the closing of its initial public offering (the "Offering") of 1,600,000 Class A ordinary shares, par value $0.0001 per share (the "Class A Ordinary Shares") at a price of $4.00 per share (the "Public Offering Price"). The Company's Class A Ordinary Shares began trading on the Nasdaq Capital Market under the symbol "MCTA" on October 21, 2025.
- 황정호 기자
- 2025-10-23 00:51
SynbioTech Brings Taiwan's Biotech Excellence to the Global Stage with TWK10® for Muscle Performance and Healthy Aging

LAS VEGAS, Oct. 23, 2025 -- In a field where scientific validation defines credibility, Synbio Tech Inc., a biotechnology company from Taiwan, is gaining international recognition with its proprietary probiotic Lactiplantibacillus plantarum TWK10®. The clinically proven strain, which will be featured at SupplySide Global 2025 from October 27–30 (Booth #6253F), has shown measurable benefits on muscle strength, endurance, and balance—offering a new microbiome-based approach to healthy aging and active living. Backed by over a decade of research, TWK10® has been evaluated
- 김갑성 기자
- 2025-10-23 00:00
Largest Milestone Payment Secured: Biokin, a Rising Chinese Pharmaceutical MNC

BEIJING, Oct. 22, 2025 -- In October 2025, a partnership between Biokin—a rising star in China's innovative pharmaceutical sector—and global pharmaceutical leader BMS triggered a $250 million milestone payment. This is believed to be the largest antibody-drug conjugate (ADC) milestone payment among hundreds of out-licensing deals involving Chinese innovative drugs. Notably, the overall transaction had previously set a record for the total value of a single-drug asset license in China. In recent years, China's dynamic pharmaceutical ecosystem has rapidly emerged as one of the wo
- 김갑성 기자
- 2025-10-22 23:39
The Blood Center in New Orleans modernizes platelet processing with FDA-cleared automation from Terumo Blood and Cell Technologies

— Second U.S. site to deploy the Reveos™ system, boosting platelet supply and reducing waste LAKEWOOD, Colo., Oct. 22, 2025 -- To help address platelet shortages and streamline blood center operations, The Blood Center in New Orleans has become the second U.S. blood center to implement the Reveos™ Automated Blood Processing System and the Lumia™ Software Platform from Terumo Blood and Cell Technologies (Terumo BCT), a medical technology company and global leader in blood management solutions. The move marks a significant step forward in transforming how blood centers process bl
- 김갑성 기자
- 2025-10-22 22:39
CathWorks Announces Key Events for TCT 2025

The CathWorks FFRangio® System to be Center Stage, Featured in Multiple Scientific Sessions, Live Cases and a Primetime Academic Satellite Program NEWPORT BEACH, Calif., Oct. 22, 2025 -- CathWorks, a global leader in digital health innovations, announced today the schedule of key events for the company during the upcoming Cardiovascular Research Foundation's annual Transcatheter Cardiovascular Therapeutics (TCT) conference taking place October 25 to 28 at the Moscone Center in San Francisco, California. The CathWorks FFRangio® System will be featured in multiple
- 김갑성 기자
- 2025-10-22 22:05
Visionary Holdings Launches Toronto-Based Joint Venture to Drive Global Commercialization of Innovative Stem Cell Therapy for Diabetes Remission, Targeting a $150 Billion Market Opportunity

TORONTO, Oct. 22, 2025 -- Visionary Holdings Inc. ("GV" or the "Company"), a technology-driven multinational enterprise listed on Nasdaq (Nasdaq: GV), today announced the signing of a strategic cooperation agreement with Jiangsu Yike Regenerative Medical Technology Co., Ltd. ("Yike") to jointly establish Visionary Yike Stemcell Technologies Inc., a Canada-based joint venture dedicated to advancing stem cell research, clinical application, and commercialization worldwide. Under the agreement, GV and Yike will leverage their respective strengths in global co
- 황정호 기자
- 2025-10-22 21:30

이전

11 12 13 14 15 16 17 18 19 20

많이 본 기사

최근기사

2025-11-04_TUE

발행인 : 최희정 | 편집인 : 김갑성 |
등록번호: 서울특별시 아53302 | 등록일 2020-09-25 | 전화번호 02-565-7119 |
주소 : 서울특별시 강남구 영동대로 602, 6층 E115 (삼성동)
Copyright @메디채널 Corp. All rights reserved.

UPDATE: 2025년 11월 04일 14시 40분